Abstract:e14513 Background: Local recurrence of Hepatocellular Carcinoma (HCC) following potentially curative resection or ablation is an inevitable risk. T cells recognizing neoantigens are present in most cancers including HCC and offer a specific and highly immunogenic target for the personalized vaccination as an adjuvant therapy. The purpose of this study is to evaluate the safety and T cell immune response of a personalized neoantigen-based mRNA loaded dendritic cell (DC) vaccine (LK101) combined with regular ablation in patients with HCC (NCT03674073). Methods: Each patient’s fresh tumor biopsy and matched peripheral blood sample were subjected to whole-exome sequencing and RNA-sequencing. Following determination of somatic mutations and gene expression, up to 30 in silico–predicted potential neoantigens were selected with bioinformatic tool. DCs were generated from the monocytes enriched by leukapheresis, followed by transfection with neoantigen-encoding mRNA through electroporation. In total, 7 doses of LK101 were administered at 1.5×107 cells/injection intradermally with 4-dose priming weekly and 3 boosters in 4-week intervals. The primary endpoint of the clinical study was safety, and key secondary endpoints were immunogenicity, overall survival and recurrence. 24 HCC patients at HKLC stage IIa were enrolled 1:1 to ablation control arm and ablation combined with DC (LK101) arm. Results: The study was completed, patients were followed up for a median of 48.4 months and 38.8 months in vaccination arm and control arm. All of adverse events were Grade 1-2. Most frequent treatment-related adverse events are injection site reactions, inclusive of local pain (63.6%), itch (27.3%) and others (27.3%), such as redness and edema. 3 patients in ablation control arm died, whereas all vaccinated patients survived. The 1-year and 2-year recurrence rates in vaccination arm compared with control arm are 18.2%, respectively. LK101 induced neoantigen-specific T cell responses were investigated by ELISpot analysis. Overall, all patients elicited at least one measurable response. Immune responses to 60-90% of neoantigen peptides were seen post vaccination across patients. Both preexisting immune response and De Novo immune response that targeted neoantigens were observed in vaccinated patients. Moreover, both CD4 and CD8 positive effector memory T cells showed the trend of increase, and PD-1 positive T cells reduced in peripheral blood of patients after vaccination. Conclusions: Combination of LK101 with ablation therapy has a manageable safety profile, showing the evidence of immune activation and potential of prolonged survival. In combination with regular ablation, neoantigen based mRNA loaded DC vaccine is a promising immunotherapy for the treatment of HCC. Clinical trial information: NCT03674073 .

Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma.

Microwave ablation and combined with adoptive immunotherapy for hepatocellular carcinoma

Multiple Courses of Immunotherapy with Different Immune Cell Types for Patients with Hepatocellular Carcinoma after Microwave Ablation.

The Effect of Adoptive Immunotherapy after Percutaneous Microwave Ablation in Recurrent Hepatocellular Carcinoma Patients with Hepatitis B: A Preliminary Study

Microwave Ablation Combined with Apatinib and Camrelizumab in Patients with Advanced Hepatocellular Carcinoma: A Single-Arm, Preliminary Study.

Long-Term Results of A Phase Ii Clinical Trial of Superantigen Therapy with Staphylococcal Enterotoxin C after Microwave Ablation in Hepatocellular Carcinoma

Clinical Study of the Ultrasound-guided Microwave Ablation Combined with Iodine-125 Implantation in the Treatment of Liver Cancer

Dendritic cell-cytokine killer combined with microwave ablation reduced recurrence for hepatocellular carcinoma compared to ablation alone

A First-in-human Study to Evaluate a Personalized Neoantigen-Based Mrna-Loaded Dendritic Cell Vaccine, in Combination with Ablation, in Patients with Hepatocellular Carcinoma.

Safety Assessment and Therapeutic Efficacy of Percutaneous Microwave Ablation Therapy Combined with Percutaneous Ethanol Injection for Hepatocellular Carcinoma Adjacent to the Gallbladder.

A Clinical Study of Thermal Monitoring Techniques of Ultrasound-Guided Microwave Ablation for Hepatocellular Carcinoma in High-Risk Locations

Microwave Ablation in Treating Intrahepatic Recurrence of Hepatocellular Carcinoma after Liver Transplantation: an Analysis of 11 Cases

Comparison of Cooled-Probe Microwave and Radiofrequency Ablation Treatment in Incipient Hepatocellular Carcinoma: A Phase Iii Randomized Controlled Trial with 6-Year Follow-Up

Outcomes of Microwave Ablation for Hepatocellular Carcinoma Adjacent to Large Vessels: a Propensity Score Analysis

Ultrasound-guided Percutaneous Microwave Ablation Assisted by Three-Dimensional Visualization Operative Treatment Planning System and Percutaneous Transhepatic Cholangial Drainage with Intraductal Chilled Saline Perfusion for Larger Hepatic Hilum Hepatocellular (D ≥ 3 Cm): Preliminary Results.

Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial

Effect of Percutaneous Microwave Ablation on Liver Cancer and Its Complications in 171 Patients

Ultrasound-guided percutaneous microwave ablation of hepatocellular carcinoma in challenging locations: oncologic outcomes and advanced assistive technology

Clinical study on microwave ablation combined with transcatheter arterial chemoembolization in treating 46 cases of primary hepatocellular carcinoma

Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional planning system combined with transhepatic arterial chemoembolization for treating single large hepatocellular carcinoma: a primary study of survival

[Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study]